Monopar TherapeuticsMNPREarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative targeted therapies for cancer patients. Its lead product candidates address unmet oncology medical needs, serving North American markets and partnering with global healthcare and research institutions to advance its development pipeline.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| Tactic Pharma LLC | 16.20% | 855.6K | — | 2024-12-17 |
| S.S. OR | 10.90% | 562.5K | — | 2024-11-06 |
| AstraZeneca PLC | 9.90% | 387.3K | — | 2024-10-28 |
| NOS. OF ABOVE PERSONS | 9.70% | 511.2K | ▲ +4.60pp | 2024-10-31 |
| Jeffrey Klunzinger | 5.24% | 692.8K | — | 2023-06-02 |
Insider Transactions
Net 90d: +$0 · buys $0 / sells $0Range:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-03-31 | Chandler Robinson | Chief Executive Officer | Option exercise | 6.7K | — | — |
| 2026-03-31 | Andrew Cittadine | Chief Operating Officer | Option exercise | 3.5K | — | — |
1–2 of 2